The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
JMA Renews Opposition for Health Coverage Review for Pharmaceuticals
The Japan Medical Association (JMA) on June 7 expressed its view on the Fiscal System Council’s budget recommendation issued late last month, reiterating its strong opposition to the proposed review on the scope of pharmaceutical health coverage. At a regular…
To read the full story
Related Article
- MOF Panel Renews Call for Full Execution of Annual Price Cuts, Urges LLP Copay Review: Budget Proposal
November 21, 2023
- Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
- MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
ORGANIZATION
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…